Evaluation of Digital Cytology for the Triage of HPV-positive Women in a Same-day "Test-triage-treat" Cervical Cancer Screening Strategy in Cameroon
Sponsor: University Hospital, Geneva
Trial Details
| Condition | Human Papillomavirus Infection, Cervical Intraepithelial Neoplasia Grade 2 (CIN2), Cervical Cancer Screening Methods |
| Intervention | HPV testing (self-sampling); Digital telecytology; AI-assisted telecytology; Thermal ablation |
| Phase | NA |
| Status | Recruiting |
| Participants | 1,800 |
| Est. Completion | 8 Sept 2026 |
| Last Updated | 24 Apr 2026 |
Primary Outcome
Diagnostic accuracy of HPV-based screening with digital cytology triage for detection of CIN2+
Eligibility Criteria
Inclusion Criteria
Inclusion Criteria: * HIV-negative women aged 30-49 and HIV-positive women aged 25-49 years old * Ability to understand study procedures and accepting voluntarily to participate by signing an informed consent form (ICF). Exclusion Criteria: * Pregnancy at the time of screening * Previous hysterectomy * Known cervical cancer * Symptoms of cervical cancer (e.g. metrorrhagia, known pelvic mass) * Conditions that can interfere with visualization of the cervix * Severe pre-existing medical conditions (e.g. advanced cancer, terminal renal failure) * Women who are not able to comply with the study protocol.
Trial Sites
Countries
This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service